Zoom Communications reported solid fourth-quarter earnings but a weaker-than-expected outlook. Broad markets are steady while defense stocks rally after no feared scenarios, including far-right ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

A transaction is expected to value the filtration business between $3.5 billion and $4 billion. KBW and UBS raised price targets on shares of Warren Buffett's Berkshire Hathaway after the conglomerate ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Drug compounders have filed a lawsuit against the FDA for removing Novo Nordisk's Wegovy and Ozempic from its shortage list. This decision restricts compounders from selling cheaper versions, despite ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...